Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ARS Pharmaceuticals Inc shares valued at $267,357 were purchased by JUSTIN CHAKMA on Nov 12 ’25. At $8.91 per share, JUSTIN CHAKMA acquired 30,000 shares.
Also, Chakma Justin purchased 138,380 shares, netting a total of over 1,227,420 in proceeds.
Before that, Lowenthal Richard E had sold 50,000 shares from its account. In a trade valued at $724,345, the PRESIDENT AND CEO traded ARS Pharmaceuticals Inc shares for $14.49 each. Upon closing the transaction, the insider’s holdings decreased to 50,000 shares, worth approximately $10.7 million.
Analysts at Roth Capital started covering the stock with ‘”a Buy”‘ outlook in a report released in early September. As of March 07, 2025, Scotiabank has initiated its “Sector outperform” rating for SPRY. Earlier on February 10, 2025, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for SPRY stock.
Analyzing SPRY Stock Performance
On last trading session, ARS Pharmaceuticals Inc [NASDAQ: SPRY] rose 2.00% to $8.94. The stock’s lowest price that day was $8.6001, but it reached a high of $9.0699 in the same session. During the last five days, there has been a drop of approximately -1.16%. Over the course of the year, ARS Pharmaceuticals Inc shares have dropped approximately -47.51%. Shares of the company reached a 52-week high of $18.90 on 06/27/25 and a 52-week low of $8.05 on 11/07/25.
Support And Resistance Levels for ARS Pharmaceuticals Inc (SPRY)
According to the 24-hour chart, there is a support level at 8.67, which, if violated, would cause prices to drop to 8.40. In the upper region, resistance lies at 9.14. The next price resistance is at 9.34. RSI (Relative Strength Index) is 43.60 on the 14-day chart, showing neutral technical sentiment.
Is ARS Pharmaceuticals Inc subject to short interest?
Stocks of ARS Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-31 dropping by -1.93 million shares to 19.76 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 21.69 million shares. A decline of -9.79% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.97 of the overall float, the days-to-cover ratio (short ratio) decline to 8.97.
Which companies own the most shares of ARS Pharmaceuticals Inc (SPRY)?
In terms of ARS Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 31 in the next 12 months, up nearly 253.48% from the previous closing price of $8.77. Analysts anticipate ARS Pharmaceuticals Inc stock to reach 32 by 2025, with the lowest price target being 30. In spite of this, 4 analysts ranked ARS Pharmaceuticals Inc stock as Buy at the end of 2025.
